NovoCure (NVCR) Competitors

Glaukos (NYSE:GKOS) and NovoCure (NASDAQ:NVCR) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, community ranking, valuation, earnings and profitability.

Do institutionals & insiders have more ownership in GKOS or NVCR?

99.0% of Glaukos shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 6.4% of Glaukos shares are held by company insiders. Comparatively, 6.3% of NovoCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has more risk and volatility, GKOS or NVCR?

Glaukos has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.

Does the media refer more to GKOS or NVCR?

In the previous week, Glaukos had 21 more articles in the media than NovoCure. MarketBeat recorded 24 mentions for Glaukos and 3 mentions for NovoCure. Glaukos' average media sentiment score of 0.29 beat NovoCure's score of 0.05 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	5 Very Positive mention(s)	1 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
NovoCure	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor GKOS or NVCR?

NovoCure received 27 more outperform votes than Glaukos when rated by MarketBeat users. However, 65.03% of users gave Glaukos an outperform vote while only 63.68% of users gave NovoCure an outperform vote.

Company	Underperform	Outperform
Glaukos	Outperform Votes 450 65.03%	Underperform Votes 242 34.97%
NovoCure	Outperform Votes 477 63.68%	Underperform Votes 272 36.32%

Which has better valuation & earnings, GKOS or NVCR?

Glaukos has higher earnings, but lower revenue than NovoCure. Glaukos is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$314.71M	22.08	-$134.66M	-$3.02	-41.73
NovoCure	$509.34M	4.69	-$207.04M	-$1.40	-15.78

Is GKOS or NVCR more profitable?

NovoCure has a net margin of -25.93% compared to Glaukos' net margin of -42.43%. Glaukos' return on equity of -18.99% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-42.43%	-18.99%	-11.47%
NovoCure	-25.93%	-41.48%	-12.74%

Do analysts rate GKOS or NVCR?

Glaukos currently has a consensus target price of $163.25, indicating a potential upside of 29.53%. NovoCure has a consensus target price of $32.67, indicating a potential upside of 47.88%. Given NovoCure's higher probable upside, analysts plainly believe NovoCure is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
NovoCure	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Glaukos beats NovoCure on 13 of the 19 factors compared between the two stocks.